|
We asked 40 industry leaders,  Which of these countries do you believe will drive most
of pharma's growth over the next 12 months?
Click here to vote.
| USA |
28% |
China |
36% |
| Brazil |
1% |
| Japan |
3% |
| Germany |
3% |
| India |
21% |
|
|
 |
|
|
|
|
|
7 October, 2014
|
|
|
European Pharma Innovation: A Critical Perspective
Economist Fabio Pammolli has been selected by the European Commission as the first author of a set of critical overviews on the state of the industry from a national, regional and global perspective. Pharm Exec recently sat down with Pammolli to hear his views on drug innovation within the European industry—and how government is measuring up to his recommendations for a dramatic change in industrial strategy to accommodate a far more competitive marketplace. Read more |
Italy’s AIFA: A Decade of Influence
In this interview with Pharm Exec, Dr. Sergio Pecorelli, Chairman of the Italian Medicines Agency (AIFA) outlines the progress of recent AIFA initiatives to raise the timeliness and efficiency of decision-making. But real challenges remain – especially in reconciling its mandate at the level of individual regions... Read more
|
Pharm Exec Global: Big Data Special
In the latest issue of the Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; Successfully integrating Big Data analytics with a company’s existing systems; In-silico modeling and real-word outcomes; and more ... Read more
|
Trouble Brewing on the European Drug-Pricing Horizon
"Better volcano forecasting", the European Union announced with pride in mid-September. The breakthrough was a new EU-funded monitoring scheme for Iceland's volatile geology. What the EU has paid less attention to is the volcano that is soon likely to blow apart its assumptions on the pricing and reimbursement of medicines, writes our Brussels correspondent Reflector .... Read more
|
|
|
|
|
